-
The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy
-
Byoung Yong Shim, Chi Hong Kim, So Hyang Song, Meyung Im Ahn, Eun Jung Hong, Sung Whan Kim, Suzy Kim, Min Seop Jo, Deog Gon Cho, Kyu Do Cho, Jinyoung Yoo, Hoon-Kyo Kim
-
Cancer Res Treat. 2005;37(6):339-343. Published online December 31, 2005
-
DOI: https://doi.org/10.4143/crt.2005.37.6.339
-
-
 Abstract
 PDF PubReader ePub
- Purpose
When used in the second-line setting, single-agent chemotherapy has produced response rates of more than 10% or median survival times greater than 4 months. We studied the safety and efficacy of using second-line single docetaxel (75 mg/m2) for advanced NSCLC patients who were previously treated with platinum-based chemotherapy in Korea. Materials and MethodsThirty-three patients with advanced NSCLC received chemotherapy from May 2002 to January 2005. We retrospectively reviewed the charts of these patients. The patients received 75 mg/m2 of doxetaxel on day 1 and this was repeated at 3-week intervals. ResultsThe median age was 63 years (range: 42~77 years); 16 patients had adenocarcinoma and 8 patients had squamous cell carcinoma. The median number of cycles was 4 (range: 1~7 cycles). Of the 33 patients, 6 patients had partial responses, 13 patients had stable disease and 14 patients had progressive disease. The response rate was 18.2%. The median overall survival was 11 months (range: 7~15 months), and the median progression free survival was 5 months (range: 3~7 months). The median response duration was 5 months (range: 4~9 months). A total of 137 cycles were evaluated for toxicity. We observed grade 3 or 4 neutropenia in 79 cycles (57.6%), grade 3 or 4 leukopenia in 46 cycles (33.6%), and grade 3 febrile neutropenia in 2 cycles (1.5%). The median nadir day was day 9 (range: day 5~19), and the median number of G-CSF injections was 2 (range: 0~6). The most common non-hematologic toxicities were myalgia/arthralgia and neurotoxicity, but any grade 3 or 4 non-hematologic toxicity was not observed. The major toxicity of this therapy was neutropenia. The absolute neutrophil count decreased relatively rapidly, but neutropenic fever or related infection was rare. There were no treatment-related deaths. ConclusionThese results revealed a satisfactory response rate (18.2%) with using docetaxel as the second-line chemotherapy for NSCLC. The second-line docetaxel was an active and well-tolerated regimen in patients with advanced NSCLC pretreated with platinum-based chemotherapy.
-
Citations
Citations to this article as recorded by  - Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Yongchang Zhang, Lianxi Song, Liang Zeng, Yi Xiong, Li Liu, Chunhua Zhou, Haiyan Yang, Zhan Wang, Qing Xia, Wenjuan Jiang, Qinqin Xu, Nong Yang
BMC Cancer.2022;[Epub] CrossRef - Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer
JoungSoon Jang, Hoon-Kyo Kim, Byoung Chul Cho, Kyung Hee Lee, Hwan-Jung Yun, In Sook Woo, Hong Suk Song, Hun-Mo Ryoo, Chi-Hong Kim, Der-Sheng Sun, Jong Wook Shin
Cancer Chemotherapy and Pharmacology.2017; 79(5): 873. CrossRef - Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review
Ricardo Fernandes, Sasha Mazzarello, Habeeb Majeed, Stephanie Smith, Risa Shorr, Brian Hutton, Mohammed FK Ibrahim, Carmel Jacobs, Michael Ong, Mark Clemons
Supportive Care in Cancer.2016; 24(4): 1583. CrossRef - Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
Keun-Wook Lee, Joo Han Lim, Jee Hyun Kim, Choon-Taek Lee, Jong Seok Lee
Journal of Korean Medical Science.2008; 23(6): 992. CrossRef - Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Yoon Ho Ko, Myung Ah Lee, Yeong Seon Hong, Kyung Shik Lee, Hyun Jin Park, Ie Ryung Yoo, Yeon Sil Kim, Young Kyoon Kim, Keon Hyun Jo, Young Pil Wang, Kyo Young Lee, Jin Hyoung Kang
The Korean Journal of Internal Medicine.2007; 22(3): 178. CrossRef
-
10,622
View
-
68
Download
-
5
Crossref
-
Expression of Caspase-3 and c-myc in Non-Small Cell Lung Cancer
-
Jin young Yoo, Chi Hong Kim, So Hyang Song, Byoung Yong Shim, Youn Ju Jeong, Meyung Im Ahn, Suji Kim, Deog Gon Cho, Min Seop Jo, Kyu Do Cho, Hong Joo Cho, Seok Jin Kang, Hoon Kyo Kim
-
Cancer Res Treat. 2004;36(5):303-307. Published online October 31, 2004
-
DOI: https://doi.org/10.4143/crt.2004.36.5.303
-
-
Abstract
PDFPubReaderePub
- Purpose
Caspase-3 is a cysteine protease that plays an important role in the process of apoptotic cell death, but little has been studied clinically on caspase-3 in lung cancer. Increased c-myc expression can result in mitosis or apoptosis, and its contribution to the pathogenesis and prognosis of lung cancer has gained interest. In the present study, the expressions of caspase-3 and c-myc, along with their possible correlations with prognostic variables, were analyzed in resected non-small cell lung carcinomas (NSCLC). Materials and MethodsArchival tumor tissues from 147 previously untreated NSCLC patients were examined by immunohistochemistry for the expressions of caspase-3 and c-myc proteins. Clinical information was obtained through the computerized retrospective database from the tumor registry. ResultsThe expressions of caspase-3 and c-myc were detected in 60 (88/147) and 16% (24/147) of tumors, respectively. No association was found between caspase-3 and c-myc expressions. A multivariate analysis demonstrated the N status and pathologic stage to be significantly correlated with poor survival (p-value=.018 and .002, respectively), but positive expression of caspase-3 was associated with a good prognosis (p=.03). ConclusionOur data suggest the involvement of caspase-3 in the tumorigenesis of NSCLC. It is also noteworthy that caspase-3 expression might be a favorable prognostic indicator in these tumors.
-
Citations
Citations to this article as recorded by - DNA Damage-Induced Ferroptosis: A Boolean Model Regulating p53 and Non-Coding RNAs in Drug Resistance
Shantanu Gupta, Daner A. Silveira, José Carlos M. Mombach, Ronaldo F. Hashimoto
Proteomes.2025; 13(1): 6. CrossRef - The Potential Prognostic Value of Glutatione-S Transferase Izoenzymes in Non-small Cell Lung Cancer
Aydın Keskin, Pınar Kaygın, Kayhan Başak, Fatma Çakmak Kazanci, Sezen Yılmaz Sarıaltın, Onur Dirican, Abbas Ali Husseini, Muharrem Atlı, Can Yılmaz, Serpil Oğuztüzün
Türk Doğa ve Fen Dergisi.2025; 14(1): 48. CrossRef - Highly in vitro anti-cancer activity of melittin-loaded niosomes on non-small cell lung cancer cells
Pooyan Honari, Delavar Shahbazzadeh, Mahdi Behdani, Kamran Pooshang Bagheri
Toxicon.2024; 241: 107673. CrossRef - Neuropilin-1 Binding Peptide as Fusion to Diphtheria Toxin Induces Apoptosis
in Non-small Cell Lung Cancer Cell Line
Sara Eghtedari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Current Pharmaceutical Design.2024; 30(17): 1317. CrossRef - Antiproliferative effect of indeno[1,2-d]thiazolo[3,2-a]pyrimidine analogues on IL-6 mediated STAT3 and role of the apoptotic pathway in albino Wistar rats of ethyl carbamate-induced lung carcinoma: In-silico, In-vitro, and In-vivo study
Archana Bharti Sonkar, Abhishek Verma, Sneha Yadav, Rohit Kumar, Jyoti Singh, Amit K. Keshari, Soniya Rani, Anurag Kumar, Dharmendra Kumar, Neeraj Kumar Shrivastava, Shubham Rastogi, Mariam K. Alamoudi, Mohd Nazam Ansari, Abdulaziz S. Saeedan, Gaurav Kait
Cancer Cell International.2024;[Epub] CrossRef - The Effect of Continuous Positive Airway Pressure (CPAP) Therapy on Serum Caspase-3 Level in Patients with Obstructive Sleep Apnea (OSA)
Mustafa Kemal Kaypak, Ali Nihat Annakkaya, Fatih Davran, Pınar Yıldız Gülhan, Uğur Yüregir
Sleep and Breathing.2024; 28(4): 1597. CrossRef - The concealed side of caspases: beyond a killer of cells
Lina Abdelghany, Chanin Sillapachaiyaporn, Boris Zhivotovsky
Cellular and Molecular Life Sciences.2024;[Epub] CrossRef - The Expression of Caspase-3 and GRIM-19 in Non-mucinous Lung Adenocarcinoma and Their Clinicopathologic Significance
Alev OK ATILGAN, Merih TEPEOĞLU, Eda YILMAZ AKÇAY, Leyla HASANALİYEVA, Dalokay KILIÇ, Handan ÖZDEMİR
Düzce Tıp Fakültesi Dergisi.2023; 25(2): 158. CrossRef - Increasing Apoptotic Effect of Cord Blood and Wharton's Jelly-derived
Mesenchymal Stem Cells on HT-29
Figen Abatay-Sel, Ayse Erol, Mediha Suleymanoglu, Gokhan Demirayak, Cigdem Kekik-Cinar, Durdane Serap Kuruca, Fatma Savran-Oguz
Current Stem Cell Research & Therapy.2023; 18(8): 1133. CrossRef - Multimolecular characteristics of cell-death related hub genes in human cancers: a comprehensive pan-cancer analysis
Dingtao Hu, Tingyu Zhang, Ziye Yan, Linlin Wang, Yuhua Wang, Nana Meng, Bizhi Tu, Ying Teng, Zhen Li, Xiaoqi Lou, Yu Lei, Xiaoshuang Ren, Yanfeng Zou, Fang Wang
Cell Cycle.2022; 21(22): 2444. CrossRef - Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study
Jin Cao, Juan J Gu, Yichen Liang, Buhai Wang
Technology in Cancer Research & Treatment.2022;[Epub] CrossRef - Global profiling of lncRNAs-miRNAs-mRNAs reveals differential expression of coding genes and non-coding RNAs in the lung of beagle dogs at different stages of Toxocara canis infection
Wen-Bin Zheng, Yang Zou, Jun-Jun He, Hany M. Elsheikha, Guo-Hua Liu, Min-Hua Hu, Shui-Lian Wang, Xing-Quan Zhu
International Journal for Parasitology.2021; 51(1): 49. CrossRef - Prognostic Significance of Eight Immune-Related Genes on Survival in Patients with Lung Squamous Cell Carcinoma
Hansheng Wu, Shujie Huang, Weitao Zhuang, Guibin Qiao
Biomarkers in Medicine.2021; 15(4): 295. CrossRef - Antitumor Effects of Carvacrol and Thymol: A Systematic Review
Laeza Alves Sampaio, Lícia Tairiny Santos Pina, Mairim Russo Serafini, Débora dos Santos Tavares, Adriana Gibara Guimarães
Frontiers in Pharmacology.2021;[Epub] CrossRef - MYC, MYCL, and MYCN as therapeutic targets in lung cancer
Daniel Massó-Vallés, Marie-Eve Beaulieu, Laura Soucek
Expert Opinion on Therapeutic Targets.2020; 24(2): 101. CrossRef - RETRACTED ARTICLE: A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers
Poonam Parashar, Chandra Bhushan Tripathi, Malti Arya, Jovita Kanoujia, Mahendra Singh, Abhishek Yadav, Shubhini A. Saraf
Drug Delivery and Translational Research.2019; 9(1): 37. CrossRef - miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9
Haitao Huang, Yuxuan Wang, Qin Li, Xiaoyan Fei, Haitao Ma, Rongkuan Hu
Cancer Letters.2019; 446: 81. CrossRef - Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival
Xuan Pu, Sarah J. Storr, Yimin Zhang, Emad A. Rakha, Andrew R. Green, Ian O. Ellis, Stewart G. Martin
Apoptosis.2017; 22(3): 357. CrossRef - MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Eun Young Kim, Arum Kim, Se Kyu Kim, Yoon Soo Chang
Lung Cancer.2017; 110: 63. CrossRef - Caspase-3 expression in tumorigenesis and prognosis of buccal mucosa squamous cell carcinoma
Jer-Shyung Huang, Cheng-Mei Yang, Jyh-Seng Wang, Huei-Han Liou, I-Chien Hsieh, Guan-Cheng Li, Sin-Jhih Huang, Chih-Wen Shu, Ting-Ying Fu, Yun-Chung Lin, Luo-Ping Ger, Pei-Feng Liu
Oncotarget.2017; 8(48): 84237. CrossRef - An epigenetic auto-feedback loop regulates TGF-β type II receptor expression and function in NSCLC
Shanzhong Yang, Yong-Jig Cho, Lin Jin, Guandou Yuan, Arunima Datta, Phillip Buckhaults, Pran K. Datta
Oncotarget.2015; 6(32): 33237. CrossRef - Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas
Yari Ciribilli, Prashant Singh, Reinhard Spanel, Alberto Inga, Jürgen Borlak
Oncotarget.2015; 6(31): 31569. CrossRef - Suppression of Dicer Increases Sensitivity to Gefitinib in Human Lung Cancer Cells
Jui-Chieh Chen, Yen-Hao Su, Ching-Feng Chiu, Yi-Wen Chang, Yang-Hao Yu, Chi-Feng Tseng, Hsin-An Chen, Jen-Liang Su
Annals of Surgical Oncology.2014; 21(S4): 555. CrossRef - Retracted: MiR‐449c targets c‐Myc and inhibits NSCLC cell progression
Li-Jun Miao, Shi-Fu Huang, Zhen-Tao Sun, Zeng-Yan Gao, Rui-xia Zhang, Ying Liu, Jing Wang
FEBS Letters.2013; 587(9): 1359. CrossRef - The Evaluation of Immunohistochemical Markers and Thymic Cortical Microenvironmental Cells in Distinguishing Thymic Carcinoma from Type B3 Thymoma or Lung Squamous Cell Carcinoma
Atsushi Hayashi, Takumi Fumon, Yukari Miki, Hiaki Sato, Tadashi Yoshino, Kiyoshi Takahashi
Journal of Clinical and Experimental Hematopathology.2013; 53(1): 9. CrossRef - Protein Signature of Lung Cancer Tissues
Michael R. Mehan, Deborah Ayers, Derek Thirstrup, Wei Xiong, Rachel M. Ostroff, Edward N. Brody, Jeffrey J. Walker, Larry Gold, Thale C. Jarvis, Nebojsa Janjic, Geoffrey S. Baird, Sheri K. Wilcox, Rossella Rota
PLoS ONE.2012; 7(4): e35157. CrossRef
-
11,205
View
-
70
Download
-
26
Crossref
-
Expression of c-kit and p53 in Non-small Cell Lung Cancers
-
Jinyoung Yoo, Chi Hong Kim, So Hyang Song, Byoung Yong Shim, Youn Ju Jeong, Meyung Im Ahn, Sung Whan Kim, Deog Gon Cho, Min Seop Jo, Kyu Do Cho, Hong Joo Cho, Hoon-Kyo Kim
-
Cancer Res Treat. 2004;36(3):167-172. Published online June 30, 2004
-
DOI: https://doi.org/10.4143/crt.2004.36.3.167
-
-
Abstract
PDFPubReaderePub
- Purpose
Increasing experimental evidence indicates that abnormal expression of c-kit may be implicated in the pathogenesis of a variety of solid tumors. It has been reported that over 70% of small cell lung cancer (SCLC) contain the c-kit receptor. In the present study, a c-kit analysis has been extended to non-small cell lung cancer (NSCLC). The expressions of p53, vascular endothelial growth factor (VEGF) and cd34, in addition to c-kit, were evaluated to investigate the correlations between these proteins and to determine their potential relationships with the clinicopathological data. Materials and MethodsParaffin-embedded tumor sections, obtained from 147 patients with NSCLC, were immunohistochemically investigated using anti-c-kit, anti-p53, anti-VEGF and anti-cd34 antibodies. Resultsc-kit was expressed in 40 (27%) of the tumors examined: 27% of the adenocarcinomas, 27% of the squamous cell carcinomas and 29% of the undifferentiated carcinomas. p53 and VEG F immunoreactivities were present in 107 (73%) and 110 (75%) carcinomas, respectively. Anti-cd34 was negative in all samples. No associations were established among these proteins. The c-kit, however, showed a strong correlation with the T factor: T1 (n=11), 0%; T2 (n=49), 16% and T3 (n=87), 37% (p=.006). ConclusionIt is suggested that in NSCLC c-kit is expressed relatively frequently and may become a therapeutic target for the patients with inoperable or recurrent c-kit positive tumors. The alterations in p53 probably constitute an early event, whereas the activated c-kit may contribute to tumor progression.
-
Citations
Citations to this article as recorded by - Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis
Ying Su, Ru Chen, Zhongcheng Han, Rong Xu, Lili Ma, Reyina Wufuli, Hongbo Liu, Fang Wang, Lei Ma, Rui Chen, Jiang Liu
Pathobiology.2021; 88(4): 267. CrossRef - A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy
Ernest Osei, Julia Lumini, Dinindu Gunasekara, Beverley Osei, Akua Asare, Raymond Laflamme
Journal of Radiotherapy in Practice.2020; 19(4): 370. CrossRef - Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression
Mi Zhang, Jing Liang, Shi-Kun Jiang, Ling Xu, Yan-Ling Wu, Annoor Awadasseid, Xiao-Yin Zhao, Xu-Qiong Xiong, Hiroshi Sugiyama, Wen Zhang
European Journal of Medicinal Chemistry.2020; 207: 112704. CrossRef - Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer
HUI XIAO, JUAN WANG, YANAN LIU, LI LI
Oncology Letters.2014; 8(2): 582. CrossRef - Protein Kinase C-δ–Mediated Recycling of Active KIT in Colon Cancer
Misun Park, Won Kyu Kim, Meiying Song, Minhee Park, Hyunki Kim, Hye Jin Nam, Sung Hee Baek, Hoguen Kim
Clinical Cancer Research.2013; 19(18): 4961. CrossRef
-
9,181
View
-
62
Download
-
5
Crossref
-
Effect of Vinorelbine, Ifosfamide and Cisplatin Combination Chemotherapy in Stage III-IV Non-Small-Cell Lung Cancer
-
Young Chul Kim, So Young Lee, Hong Joo Cho, Jung A Kim, So Hyang Song, Chi Hong Kim, Hoon Kyo Kim, Meyung Im Ahn, Jin Young You, Sung Whan Kim, Deng Gon Cho, Kyu Do Cho, Jin Hyung Kang
-
Cancer Res Treat. 2002;34(5):352-356. Published online October 31, 2002
-
DOI: https://doi.org/10.4143/crt.2002.34.5.352
-
-
Abstract
PDF
- PURPOSE
To evaluate the response rates, toxicitiesy, and survival rates, to vinorelbine (Navelbine(R)), cisplatin and ifosfamide combination chemotherapy, of the patients with inoperable NSCLC (stage III and IV), who received vinorelbine (Navelbine(R)), cisplatin, ifosfamide combinationthe mentioned chemotherapy every 4 weeks.
MATERIALS AND METHODS
This study included 26 patients with inoperable NSCLC (stage III and IV), who attended St.
Vincent's Hospital Bbetween April 1999 and December 2001, 26 patients were included at St.Vincent's Hospital. The chemotherapy regimen consisted of vinorelbine (25 mg/m2 on days 1 and 8), ifosfamide (1,500 mg/m2 on days 1- and 2 with mesna), and cisplatin (30 mg/m2 on days 1- to 3). The cycles were administered every 4 weeks. A 25% reduction in the doses reduction was applied into subsequent courses if there werewas grade 3~4 neutropenia.
RESULTS
The median age was 63 (range, 44~73) years and the male : to female ratio was 19 : 7. One patient had stage IIIa, 6 had stage IIIb and 19 had stage IV. Twenty two patients had an ECOG performance status of 0 or 1, andwith 4 hadhave one of 2. Eighteen of the patients had adenocarcinoma, 7 had squamous cell carcinomas, and 1 had an undifferentiated NSCLC. Two patients were innot able to be evaluatedble due to follow-up loss. Among Of the 24 patients able to be evaluatedble patients, 1 patient had a complete response and 9 patients hada partial responses, and thewith an overall response rate wasof 41.7%. During a total of 104 cycles, grade 3 neutropenia occurred in 29%, grade 4 neutropenia in 12%, grade 3~4 thrombocytopenia in 4%, grade 3 anemia in 11%, and grade 3~4 mucositis in 2%. The mean time to progression was 6.4 months (range 1~13) and the median overall survival was 10 months (range 1.5~32).
CONCLUSION
The combination of vinorelbine, ifosfamide and cisplatin, in the dose and schedule employed in this study, shows an response rate of 41.7%, but, because grade 3- or 4 neutropenia occurred in 41%, a careful investigation is needed.
|
KCA
